Zelira Therapeutics Ltd continues to focus on the expansion of commercialisation activities and revenue generation from its new clinically tested products, with the strategy expected to lead to the launch of a suite of new cannabinoid-based products over FY22. Commercialisation plans are focused on generating revenues from the multiple products it has launched into the Australian and US markets.